A single-dose membrane-anchored F1/LcrV mRNA vaccine confers protection against pneumonic plague: a preclinical study
Year: 2026
Type: article
Abstract: BACKGROUND: The success of mRNA-lipid nanoparticle (LNP) platforms has prompted significant interest in their application against bacterial pathogens. However, adapting these platforms requires optimising host-expressed antigen structure to ensure robust immunogenicity. While membrane anchoring enhances the efficacy of viral mRNA vaccines, its application in bacterial mRNA platforms remains largely unexplored. Plague, caused by the Gram-negative bacterium Yersinia pestis, has been one of the most devastating diseases throughout human history. Despite extensive studies, there are no licenced vaccines available. METHODS: We developed a bivalent mRNA-LNP vaccine against Y. pestis, utilising the major antigens F1 and LcrV (5 μg of each mRNA). We evaluated glycosylphosphatidylinositol (GPI)-anchored and transmembrane (TM) variants alongside secreted native and hFc-conjugated formats to assess immunological profiles and determine protective efficacy in a murine model of pneumonic plague. FINDINGS: Membrane-tethering of F1 and LcrV antigens improved overall immunogenicity. Whereas secreted native and hFc-conjugated variants elicited predominantly cell-mediated and serological immune responses, respectively, the membrane-anchored bivalent mRNA vaccine generated a robust, protective immune response. This dual humoural and cellular immunity facilitated robust (87.5%, 7/8 mice) protection following a single-dose vaccination. INTERPRETATION: By progressing towards the single-dose biodefense benchmark prioritised by the World Health Organisation Target Product Profile, this membrane-anchored construct emerges as a promising translational candidate for a rapid-response plague vaccine. Ultimately, this study demonstrates that extending established antigen-tethering strategies to bacterial targets may be a highly effective approach for generating the potent immunity required to overcome complex bacterial infections. FUNDING: This research was supported by the Israeli Science Foundation (grants 2012/20, 842/25), the Lewis Trust and the Shmunis Family Trust.
Source: EBioMedicine
Institutions: Israel Institute for Biological Research, Tel Aviv University
Language: English
Subfield: Infectious Diseases
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $5,780
Funder: Israel Science Foundation
OpenAlex ID: W7235836423
